Biocon gets Health Canada denosumab biosimilar nod 2026

Approval outcome and key dates

Biocon Limited (BSE: 532523; NSE: BIOCON) said Health Canada granted a Notice of Compliance (NOC) for two denosumab biosimilars, Bosaya and Vevzuo. The company said the NOC was issued on April 3, 2026, and the update was communicated on April 21, 2026. Bosaya is positioned as a biosimilar to Prolia, while Vevzuo is positioned as a biosimilar to Xgeva. Denosumab products are used in bone health and in certain cancer-related bone complications. Biocon framed the approval as part of its efforts to expand access to biosimilars in key global markets. The development adds two more products to Biocon’s biosimilars portfolio in Canada. The company did not provide a launch date in the text provided.

What Health Canada approved: products and presentations

Health Canada approved both products in what Biocon described as the most common presentations. Bosaya was approved as a 60 mg/mL injection for subcutaneous use in a prefilled syringe. Vevzuo was approved as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial. Biocon stated that denosumab products increase bone mass and treat osteoporosis, and are also used in bone complications associated with cancer. The approval is specific to denosumab and aligns the products to their reference biologics, Prolia and Xgeva. Biocon’s update also included safety and monitoring points typically highlighted in product information. The company directed readers to the full Product Monograph for additional details.

Indications cleared for Bosaya (denosumab)

Biocon listed multiple osteoporosis and bone-mass indications for Bosaya. It is approved for postmenopausal women with osteoporosis at high risk for fracture. It is also approved to increase bone mass in men with osteoporosis at high risk for fracture. Another approved use is to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy (ADT) who are at high risk for fracture. Bosaya is also approved to increase bone mass in women with nonmetastatic breast cancer receiving adjuvant aromatase inhibitor (AI) therapy. In addition, it is approved to increase bone mass in women and men at high risk for fracture due to sustained systemic glucocorticoid therapy and fracture who are starting or have recently started long-term glucocorticoid therapy.

Indications cleared for Vevzuo (denosumab)

Biocon said Vevzuo is approved to reduce the risk of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumours. It is also approved for adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. A further approved use is the treatment of hypercalcemia of malignancy that is refractory to intravenous bisphosphonate. These indications align Vevzuo to Xgeva’s clinical positioning in oncology and related bone complications. Biocon’s note links these approvals to the role of denosumab in preventing bone breakdown and related events.

Evidence package cited by Biocon

Biocon said Health Canada’s decision was based on a “comprehensive package” of analytical, nonclinical, and clinical data. The company stated this package demonstrated Bosaya and Vevzuo are highly similar to their reference products, Prolia and Xgeva, respectively. Biocon also said there were no clinically meaningful differences in quality, safety, or efficacy. The update did not provide trial sizes, endpoints, or study identifiers. It also did not describe any post-approval requirements beyond product information and monitoring language. The company’s language is consistent with a biosimilar approval pathway that focuses on totality of evidence.

Safety, precautions, and monitoring points highlighted

For Bosaya, Biocon highlighted hypocalcemia as a key warning and said it must be corrected with adequate calcium and vitamin D prior to starting therapy. It also noted that clinically significant hypersensitivity reactions, including anaphylaxis, have been reported with denosumab. For infections, the text referenced serious infections leading to hospitalisation reported in women with postmenopausal osteoporosis, including skin infections predominantly cellulitis, and infections of the abdomen, urinary tract, and ear, as well as endocarditis. The company said monitoring of calcium is recommended before each dose.

For Vevzuo, Biocon stated it can cause severe symptomatic hypocalcemia and cited fatal cases, listing example symptoms including altered mental status, tetany, seizures, and QTc prolongation. The company also referenced monitoring of calcium levels prior to the initial dose, within two weeks after the initial dose, and when symptoms suggest hypocalcemia, with additional monitoring for patients with risk factors. The text also mentioned osteonecrosis of the jaw (ONJ), atypical femoral fracture, and multiple vertebral fractures that may occur following discontinuation, particularly in patients with risk factors such as osteoporosis or prior fractures.

Why the approval matters: patient access and disease burden

Biocon said the approvals have the potential to benefit more than 2 million adults with osteoporosis. It also referenced “hundreds of patients annually” with bone metastasis, describing it as a common complication of advanced cancer. Denosumab is described as a human monoclonal antibody that targets and binds to RANKL, which is essential for osteoclast formation, function, and survival. By blocking RANKL, denosumab reduces bone breakdown and increases bone mass and strength. Biocon’s messaging focused on access to biosimilars, which can broaden treatment options where reference biologics are used. The company did not provide pricing, reimbursement, or formulary details in the text provided.

Management commentary and stated strategy

Shreehas Tambe, CEO and Managing Director of Biocon Ltd., said the Health Canada approval of Bosaya and Vevzuo is an important milestone as the company expands access to high-quality biosimilars in key global markets. He added that the approval reflects Biocon’s scientific and regulatory capabilities. The statement also positioned the products within Biocon’s efforts to serve patients living with osteoporosis and cancer-related bone conditions. Biocon said the approvals further strengthen its portfolio of affordable biologic therapies across immunology and oncology. No additional forward guidance, such as sales targets or launch timelines, was included.

Snapshot of the approval

Biocon’s broader biosimilars footprint (as disclosed)

Biocon described itself as a global biopharmaceutical company headquartered in Bengaluru, operating in more than 120 countries. It said it has commercialized 12 biosimilar products and 30+ generic formulations globally. The company also stated it has a research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. Its footprint, as mentioned, includes seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon also noted it was included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year. These details were included as part of the company background accompanying the Canada approval.

Conclusion

Biocon’s Canada NOC for Bosaya and Vevzuo adds two denosumab biosimilars aligned to Prolia and Xgeva, with approved presentations and a broad set of osteoporosis and oncology-related indications. The company says the approval rests on analytical, nonclinical, and clinical evidence supporting biosimilarity with no clinically meaningful differences in quality, safety, or efficacy. Next steps, including commercial timing and patient access pathways, were not specified in the text provided, with Biocon directing readers to the full Product Monograph for further information.